ARGS Argos Therapeutics Inc.

0.16
-0.00  -1%
Previous Close 0.17
Open 0.17
Price To book -0.44
Market Cap 9010360
Shares 54,974,739
Volume 2,076,746
Short Ratio 0.88
Av. Daily Volume 3,513,911

SEC filingsSee all SEC filings

  1. 8-K - Current report 171102508
  2. 8-K - Current report 171098688
  3. 8-K - Current report 171080099
  4. 8-K - Current report 171069165
  5. S-8 - Securities to be offered to employees in employee benefit plans 171061087

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced September 26, 2017 with interim data due 2H 2018.
ARGX-113
Pemphigus vulgaris (PV)
Phase 3 trial recommended be discontinued for futility - February 22, 2016. Noted April 18, 2017 that it intends to continue the trial to 290 events (analysis of overall survival) 1H 2018.
rocapuldencel-T (AGS-003) ADAPT Trial
Metastatic renal cell carcinoma (mRCC)
Phase 2 initiated 1Q 2016. Ongoing as of November 2016.
rocapuldencel-T (AGS-003)
Non-Small Cell Lung Cancer
Phase 2 second stage commenced dosing July 2016. Ongoing as of March 2017.
AGS-004
HIV
Phase 2 trial initial data due 2H 2017.
rocapuldencel-T (AGS-003)
Early stage renal cell carcinoma (RCC) - cancer

Latest News

  1. NasdaqGM Healthcare Industry: A Deep Dive Into Argos Therapeutics Inc (ARGS)
  2. ETFs with exposure to Argos Therapeutics, Inc. : October 11, 2017
  3. Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors
  4. ETFs with exposure to Argos Therapeutics, Inc. : September 26, 2017
  5. Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
  6. Argos Therapeutics Inc (ARGS): What Does It Mean For Your Portfolio?
  7. Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress
  8. Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir
  9. ETFs with exposure to Argos Therapeutics, Inc. : August 31, 2017
  10. Argos Therapeutics, Inc. :ARGS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  11. Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress
  12. Argos Therapeutics reports 2Q loss
  13. Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
  14. Today's Research Reports on Stocks to Watch: Argos Therapeutics and Tetraphase Pharmaceuticals
  15. Argos Reports Immunogenicity Results of AGS-004 in HIV Program
  16. ETFs with exposure to Argos Therapeutics, Inc. : June 29, 2017

SEC Filings

  1. 8-K - Current report 171102508
  2. 8-K - Current report 171098688
  3. 8-K - Current report 171080099
  4. 8-K - Current report 171069165
  5. S-8 - Securities to be offered to employees in employee benefit plans 171061087
  6. EFFECT - Notice of Effectiveness 171055998
  7. S-3 - Registration statement under Securities Act of 1933 171036501
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017662
  9. 8-K - Current report 171000123
  10. DEF 14A - Other definitive proxy statements 17951627